PRPH_OUT_1 [2025-03-25 10:17:43 -0400] 2088 Bytes | 574 tokens | Cum: 574 tkns (7.17% of 8k)
==========================================================================

Booyah, my friends! It's already 10:17:41 AM on Tue Mar 25, 2025 -0400, and I've got my eyes locked on ProPhase Labs (PRPH), pushing up to 0.5399 from 0.4293. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

Here's the first list of news for ProPhase Labs:

C1 - Mar-18-25 03:30PM - Q1 Virtual Investor Summit: On-Demand Presentations Now Live
C2 - Mar-07-25 08:00AM - ProPhase Labs to Present at the Investor Summit Virtual on March 11
C3 - Mar-05-25 09:55AM - Bears are Losing Control Over ProPhase Labs (PRPH), Here's Why It's a 'Buy' Now
C4 - Feb-26-25 08:00AM - Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
C5 - Feb-25-25 08:00AM - ProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Multi-Media Infrastructure with Telehealth Physician Networks for Prescription Drugs
C6 - Feb-20-25 08:00AM - ProPhase Labs Announces Excellent Progress with Crown Medical Collections Targeting Over $50 Million in Net Near-Term Cash Recovery from COVID-19 Receivables
C7 - Feb-18-25 08:00AM - ProPhase Labs hires Stuart Hollenshead as COO, the former COO and CBO of Barstool Sports
C8 - Jan-22-25 08:00AM - ProPhase Labs Announces Closing of $23.6 Million Sale of Pharmaloz Manufacturing to Houston-Based Private Equity Firm

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on ProPhase Labs (PRPH)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

PRPH_OUT_3 [2025-03-25 10:17:45 -0400] 1038 Bytes | 248 tokens | Cum: 824 tkns (10.30% of 8k)
==========================================================================

Showing C3 (chunk 1 of 5): C3:
**Bears are Losing Control Over ProPhase Labs (PRPH), Here's Why It's a 'Buy' Now**
Date: Mar-05-25 09:55AM
Source: (Zacks)
URL: https://finance.yahoo.com/news/bears-losing-control-over-prophase-145506559.html

Shares ofProPhase Labs, Inc.(PRPH) have been struggling lately and have lost 21% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road.

While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts about the future earnings of this company is a solid fundamental factor that enhances the prospects of a trend reversal for the stock.

This is one of the popular price patterns in candlest

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PRPH_OUT_5 [2025-03-25 10:17:47 -0400] 923 Bytes | 267 tokens | Cum: 1093 tkns (13.66% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-24T12:10:50Z - 12 Health Care Stocks Moving In Monday's Pre-Market Session - Capstone Holding (NASDAQ:CAPS), Allari...
A2 - 2025-03-21T10:49:49Z - North American Morning Briefing : Stock Futures Fall as Focus Shifts From Fed to Tariffs...
A3 - 2025-03-18T20:00:20Z - Investor Summit Group: Q1 Virtual Investor Summit: On-Demand Presentations Now Live...
A4 - 2025-03-18T19:33:02Z - Q1 Virtual Investor Summit: On-Demand Presentations Now Live...
A5 - 2025-03-14T10:41:42Z - North American Morning Briefing : Stock Futures -2-...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PRPH_OUT_7 [2025-03-25 10:17:48 -0400] 1038 Bytes | 308 tokens | Cum: 1403 tkns (17.54% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**12 Health Care Stocks Moving In Monday's Pre-Market Session - Capstone Holding (NASDAQ:CAPS), Allarity Therapeutics (NASDAQ:ALLR)**Date: 2025-03-24Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44455940/12-health-care-stocks-moving-in-mondays-pre-market-sessionGainers Windtree Therapeutics WINT stock increased by 39.2% to $2.06 during Monday's pre-market session. The market value of their outstanding shares is at $1.5 million. Allarity Therapeutics ALLR shares moved upwards by 20.2% to $1.19. The market value of their outstanding shares is at $5.2 million. Capstone Holding CAPS stock rose 19.18% to $2.05. The market value of their outstanding shares is at $2.8 million. Tharimmune THAR shares rose 17.94% to $1.7. The market value of their outstanding shares is at $3.2 million. Regencell Bioscience RGC share

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PRPH_OUT_9 [2025-03-25 10:17:50 -0400] 1038 Bytes | 305 tokens | Cum: 1710 tkns (21.38% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): s increased by 17.7% to $69.01. The company's market cap stands at $898.0 million. ProPhase Labs PRPH stock rose 16.54% to $0.36. The market value of their outstanding shares is at $10.8 million. Losers 23andMe Holding ME stock declined by 44.1% to $1.0 during Monday's pre-market session. The market value of their outstanding shares is at $26.8 million. Unity Biotechnology UBX shares decreased by 37.0% to $1.15. The market value of their outstanding shares is at $19.3 million. TransCode Therapeutics RNAZ shares decreased by 32.6% to $0.75. Impact BioMedical IBO stock declined by 13.92% to $4.27. The market value of their outstanding shares is at $49.1 million. SunLink Health Systems SSY shares decreased by 12.46% to $0.95. The market value of their outstanding shares is at $6.6 million. Helius Medical Tech HSDT stock fell 10.89% to $0.38. The company's market cap stands at $1.4 million.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PRPH_OUT_11 [2025-03-25 10:17:52 -0400] 1034 Bytes | 311 tokens | Cum: 2023 tkns (25.29% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-11-08T04:37:00Z - ProPhase Labs Announces Pricing of Public Offering of Common Stock
B2 - 2024-08-07T13:01:00Z - Antibody Production Market to Surpass USD 36.49 Billion by 2032 Driven by Escalating Demand for Targeted Therapies and Technological Advancements | Research by SNS Insider
B3 - 2024-06-06T12:00:00Z - Rare Stock Picks In May 2024 - From 29 Discerning Analysts
B4 - 2024-05-09T19:40:00Z - ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated
B5 - 2024-05-07T12:10:10Z - Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
B6 - 2024-05-06T21:10:03Z - Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PRPH_OUT_13 [2025-03-25 10:17:55 -0400] 673 Bytes | 180 tokens | Cum: 2205 tkns (27.56% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**ProPhase Labs Announces Pricing of Public Offering of Common Stock**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/11/08/2977360/0/en/ProPhase-Labs-Announces-Pricing-of-Public-Offering-of-Common-Stock.htmlProPhase Labs, Inc. (NASDAQ: PRPH) announced the pricing of its underwritten public offering of 4,170,000 shares of common stock at $0.72 per share, raising approximately $3 million. The company plans to use the net proceeds for working capital and general corporate purposes.

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PRPH_OUT_15 [2025-03-25 10:17:57 -0400] 1139 Bytes | 323 tokens | Cum: 2597 tkns (32.46% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-02-21 8-K Item 7.01 Regulation FD Disclosure.

A copy of the Companys press release dated February 18, 2025, relating to the announcement described in Item 5.02, is furnished as Exhibit 99.1 to this Form 8-K.

The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not ...

S2 - 2025-02-21 8-K Item 7.01 Regulation FD Disclosure.

A copy of the Companys press release dated February 18, 2025, relating to the announcement described in Item 5.02, is furnished as Exhibit 99.1 to this Form 8-K.

The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not ...

S7 - 2025-01-30 8-K Item 1.01 Entry into a Material Definitive Agrmt.

Common Stock Purchase Agrmt

On January 29, 2025, ProPhase Labs, Inc. (the Company, we, us and our) entered into a common stock purchase agreement (the Purchase Agrmt) with an equity line investor (the Investor), wh...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PRPH_OUT_17 [2025-03-25 10:18:04 -0400] 1038 Bytes | 248 tokens | Cum: 2847 tkns (35.59% of 8k)
==========================================================================

Showing S7 (chunk 1 of 6): S7:
Item 1.01 Entry into a Material Definitive Agreement.

Common Stock Purchase Agreement

On January 29, 2025, ProPhase Labs, Inc. (the Company, we, us and our) entered into a common stock purchase agreement (the Purchase Agreement) with an equity line investor (the Investor), whereby the Company may offer and sell, from time to time at its sole discretion, and whereby the Investor has committed to purchase, up to an aggregate of $7,730,973 of shares (the Purchase Shares) of the Companys common stock, par value $0.0005 per share (the common stock), subject to the conditions and limitations set forth in the Purchase Agreement.

At any time after the date on which all the conditions precedents for the sale of Purchase Shares under the Purchase Agreement have been satisfied (the Commencement Date), and so long as the closing sale price of the common stock is equal to or greater than $0

-- More of this article? (say: MOR) or Next section? (say: NEX) (only 3 chars. - please don't summarize yet)

PRPH_OUT_19 [2025-03-25 10:18:22 -0400] 4771 Bytes | 1379 tokens | Cum: 4336 tkns (54.20% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+----------------------+-------------------------+------------------------+------------------------+
| Volume: 901,620 | SMA50: 17.39% | Market Cap: 14.99M | Option/Short: Yes / Yes | Sales past 5Y: 120.73% | Sales Surprise: 11.56% |
+-------------------+-----------------------+----------------------+-------------------------+------------------------+------------------------+
| Avg Volume: 9.87M | SMA200: -72.68% | Shs Outstand: 29.87M | Short Float: 6.30% | Employees: 113 | EPS Surprise: -12.90% |
+-------------------+-----------------------+----------------------+-------------------------+------------------------+------------------------+
| Rel Volume: 0.71 | Perf Week: 28.36% | Shs Float: 26.37M | Short Ratio: 0.17 | Debt/Eq: 0.78 | P/E: - |
+-------------------+-----------------------+----------------------+-------------------------+------------------------+------------------------+
| RSI (14): 57.74 | Perf Month: -6.03% | Inst Own: 8.10% | Short Interest: 1.66M | Sales Y/Y TTM: -79.66% | Earnings: Nov 13 BMO |
+-------------------+-----------------------+----------------------+-------------------------+------------------------+------------------------+
| ATR (14): 0.08 | Perf Quarter: -23.15% | Insider Own: 11.73% | Beta: -0.62 | ROE: -58.71% | |
+-------------------+-----------------------+----------------------+-------------------------+------------------------+------------------------+
| SMA20: 21.96% | Index: - | Insider Trans: 0.00% | Sales Q/Q: -62.39% | ROI: -46.12% | |
+-------------------+-----------------------+----------------------+-------------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

No transactions recorded.

Inside Trans: ProPhase Labs, Inc. (PRPH) by Hollenshead Stuart (Chief Operating Officer) on 2025-02-17
- Option (right to buy): 500000 shares at $0 (D)

Inside Trans: ProPhase Labs, Inc. (PRPH) by GLECKEL LOUIS MD (Unknown Title) on 2025-02-14
- Option (right to buy): 100000 shares at $0 (D)

Inside Trans: ProPhase Labs, Inc. (PRPH) by Hirsch Warren (Unknown Title) on 2025-02-14
- Option (right to buy): 100000 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: ProPhase Labs, Inc. Common Stock (DE)
Market Cap: N/A
Shares Outstanding: N/A
Sector: PHARMACEUTICAL PREPARATIONS

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 12753000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -27756000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.5516
Average Volume: 2094918.36
30-Day High: 0.5516
30-Day Low: 0.3088

[Detailed Financials: Q3 2024]
- Total Assets: $91,808,000.0
- Total Liabilities: $53,682,000.0
- Total Equity: $38,126,000.0
- Current Assets: $42,235,000.0
- Current Liabilities: $28,698,000.0

[Income Statement: Q3 2024]
- Revenue: $3,146,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.35

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-1,271,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $93,678,000.0
- Total Liabilities: $49,602,000.0
- Total Equity: $44,076,000.0
- Current Assets: $44,143,000.0
- Current Liabilities: $28,012,000.0

[Income Statement: Q2 2024]
- Revenue: $2,474,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.33

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $629,000
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

PRPH_OUT_21 [2025-03-25 10:18:27 -0400] 676 Bytes | 167 tokens | Cum: 4793 tkns (59.91% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

PRPH_IN_23 [2025-03-25 10:18:28 -0400] 126 Bytes | 29 tokens | Cum: 4890 tkns (61.12% of 8k)
==========================================================================

====================================
[2025-03-25 07:18:28] # Analysis Completed
Elapsed Time: 47.25 seconds